JP2015500236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500236A5 JP2015500236A5 JP2014544901A JP2014544901A JP2015500236A5 JP 2015500236 A5 JP2015500236 A5 JP 2015500236A5 JP 2014544901 A JP2014544901 A JP 2014544901A JP 2014544901 A JP2014544901 A JP 2014544901A JP 2015500236 A5 JP2015500236 A5 JP 2015500236A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- weight
- solid form
- dihydropyrazino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 239000007787 solid Substances 0.000 claims 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- -1 6- (2-hydroxypropan-2-yl) pyridin-3-yl Chemical group 0.000 claims 5
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical compound OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 claims 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 3
- 229920003084 Avicel® PH-102 Polymers 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 235000021355 Stearic acid Nutrition 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 3
- 229960001021 lactose monohydrate Drugs 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 3
- 230000037361 pathway Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000008117 stearic acid Substances 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 238000001757 thermogravimetry curve Methods 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566109P | 2011-12-02 | 2011-12-02 | |
| US61/566,109 | 2011-12-02 | ||
| US201261647288P | 2012-05-15 | 2012-05-15 | |
| US61/647,288 | 2012-05-15 | ||
| US201261653439P | 2012-05-31 | 2012-05-31 | |
| US61/653,439 | 2012-05-31 | ||
| US201261670419P | 2012-07-11 | 2012-07-11 | |
| US61/670,419 | 2012-07-11 | ||
| PCT/US2012/067172 WO2013082344A1 (en) | 2011-12-02 | 2012-11-30 | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016215572A Division JP2017048227A (ja) | 2011-12-02 | 2016-11-02 | ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（トランス）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンの薬剤組成物、その固体形態、およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015500236A JP2015500236A (ja) | 2015-01-05 |
| JP2015500236A5 true JP2015500236A5 (enExample) | 2015-12-24 |
| JP6076370B2 JP6076370B2 (ja) | 2017-02-08 |
Family
ID=47324465
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014544901A Active JP6076370B2 (ja) | 2011-12-02 | 2012-11-30 | ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（トランス）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンの薬剤組成物、その固体形態、およびその使用方法 |
| JP2016215572A Pending JP2017048227A (ja) | 2011-12-02 | 2016-11-02 | ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（トランス）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンの薬剤組成物、その固体形態、およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016215572A Pending JP2017048227A (ja) | 2011-12-02 | 2016-11-02 | ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（トランス）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンの薬剤組成物、その固体形態、およびその使用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9403829B2 (enExample) |
| EP (1) | EP2785325B1 (enExample) |
| JP (2) | JP6076370B2 (enExample) |
| KR (1) | KR102040997B1 (enExample) |
| CN (1) | CN104093398B (enExample) |
| AU (1) | AU2012304276B2 (enExample) |
| BR (1) | BR112014013332B1 (enExample) |
| CA (2) | CA2857155C (enExample) |
| CO (1) | CO6990726A2 (enExample) |
| EA (1) | EA026390B1 (enExample) |
| EC (1) | ECSP14007473A (enExample) |
| ES (1) | ES2694413T3 (enExample) |
| IL (1) | IL232827B (enExample) |
| IN (1) | IN2014CN04037A (enExample) |
| MX (1) | MX363034B (enExample) |
| MY (1) | MY169749A (enExample) |
| NI (1) | NI201400052A (enExample) |
| PE (1) | PE20141696A1 (enExample) |
| PH (2) | PH12014501230A1 (enExample) |
| SG (2) | SG11201402766UA (enExample) |
| UA (1) | UA114496C2 (enExample) |
| WO (1) | WO2013082344A1 (enExample) |
| ZA (1) | ZA201403865B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912850WA (en) | 2011-10-19 | 2020-02-27 | Signal Pharm Llc | Treatment Of Cancer With TOR Kinase Inhibitors |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| EP2945636B1 (en) | 2013-01-16 | 2017-06-28 | Signal Pharmaceuticals, LLC | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| AU2014254057A1 (en) | 2013-04-17 | 2015-11-05 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
| NZ629411A (en) | 2013-04-17 | 2017-06-30 | Signal Pharm Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| SG11201508527VA (en) | 2013-04-17 | 2015-11-27 | Signal Pharm Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| TW201526897A (zh) * | 2013-04-17 | 2015-07-16 | Signal Pharm Llc | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| ES2944478T3 (es) * | 2013-04-17 | 2023-06-21 | Signal Pharm Llc | 1-etil-7-(2-metil-6-(1H-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino[2,3-b]pirazin-2(1H)-ona para tratar el glioblastoma multiforme |
| KR102242505B1 (ko) | 2013-04-17 | 2021-04-20 | 시그날 파마소티칼 엘엘씨 | 암 치료용 tor 키나제 억제제 및 시티딘 유사체를 포함하는 병용 요법 |
| BR112015026257B1 (pt) * | 2013-04-17 | 2022-12-20 | Signal Pharmaceuticals, Llc | Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit |
| MX368286B (es) * | 2013-04-17 | 2019-09-27 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. |
| JP6401250B2 (ja) * | 2013-05-29 | 2018-10-10 | シグナル ファーマシューティカルズ，エルエルシー | ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法 |
| US9718824B2 (en) * | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
| US9737535B2 (en) | 2014-04-16 | 2017-08-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
| AU2015289929A1 (en) | 2014-07-14 | 2017-03-02 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| EP3641772B1 (en) | 2017-06-22 | 2023-08-02 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
| CN112409399B (zh) * | 2019-08-20 | 2022-06-28 | 德琪(浙江)医药科技有限公司 | 一种药物中间体化合物的制备方法 |
| US20220380348A1 (en) * | 2019-10-04 | 2022-12-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Axl inhibitor formulations |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3507866A (en) | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
| US3567725A (en) | 1968-11-20 | 1971-03-02 | Merck & Co Inc | Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones |
| US4294837A (en) | 1980-03-28 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use |
| US4294836A (en) | 1980-03-24 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use |
| US4317909A (en) | 1980-03-24 | 1982-03-02 | Sterling Drug Inc. | Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones |
| US4309537A (en) | 1980-03-28 | 1982-01-05 | Sterling Drug Inc. | Production of imidazo[4,5-b]pyridin-2-ones or thiones |
| GB8709448D0 (en) | 1987-04-21 | 1987-05-28 | Pfizer Ltd | Heterobicyclic quinoline derivatives |
| JPS63275582A (ja) | 1987-05-02 | 1988-11-14 | Naade Kenkyusho:Kk | ２−アミノイミダゾ〔４，５−ｂ〕ピリジン誘導体の製造方法 |
| DD262026A1 (de) | 1987-07-10 | 1988-11-16 | Akad Wissenschaften Ddr | Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen |
| FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
| US4963561A (en) | 1990-02-28 | 1990-10-16 | Sterling Drug Inc. | Imidazopyridines, their preparation and use |
| TW274550B (enExample) | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
| DE19601627A1 (de) | 1996-01-18 | 1997-07-24 | Bayer Ag | Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone |
| US6031105A (en) | 1996-04-09 | 2000-02-29 | Pfizer Inc | Substituted pyridines |
| ES2230719T3 (es) | 1997-09-26 | 2005-05-01 | Zentaris Gmbh | Compuestos basados en azabencimidazol para modular una funcion de proteina-quinasa de serina/treonina. |
| ZA9810490B (en) | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
| JP2003146987A (ja) | 1999-05-31 | 2003-05-21 | Dainippon Pharmaceut Co Ltd | ２−アリールプリン−９−アセトアミド誘導体 |
| JP3814125B2 (ja) | 1999-06-02 | 2006-08-23 | 大日本住友製薬株式会社 | ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬 |
| JP2002100363A (ja) | 2000-09-25 | 2002-04-05 | Mitsubishi Chemicals Corp | リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池 |
| JP2002167387A (ja) | 2000-11-29 | 2002-06-11 | Dainippon Pharmaceut Co Ltd | ２−（７，８−ジヒドロ−８−オキソ−９ｈ−プリン−９−イル）酢酸誘導体 |
| MXPA03004245A (es) | 2000-12-12 | 2003-09-22 | Neurogen Corp | Espiro[isobenzofuran-1,4'piperidin]-3-onas y 3h-espiroisobenzofuran-1,4'-piperidinas. |
| WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| HRP20040213A2 (en) | 2001-09-04 | 2005-02-28 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments |
| JP2005506350A (ja) | 2001-10-18 | 2005-03-03 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン阻害薬としての１，４−二置換ベンゾ−縮合尿素化合物 |
| US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
| AU2003232071A1 (en) | 2002-05-06 | 2003-11-17 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
| US20040204420A1 (en) | 2002-08-05 | 2004-10-14 | Rana Tariq M. | Compounds for modulating RNA interference |
| US7199119B2 (en) | 2002-10-31 | 2007-04-03 | Amgen Inc. | Antiinflammation agents |
| WO2004065378A1 (en) | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| KR100983462B1 (ko) | 2003-02-26 | 2010-09-27 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 디하이드로프테리디논, 이의 제조방법 및 약제로서의 이의 용도 |
| GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
| JP2006524289A (ja) | 2003-04-23 | 2006-10-26 | ワイス・ホールディングズ・コーポレイション | Ｐｅｇ−ワートマニンコンジュゲート |
| EP4032897B1 (en) | 2003-05-30 | 2025-01-29 | Gilead Pharmasset LLC | Modified fluorinated nucleoside analogues |
| US7476665B2 (en) | 2003-06-26 | 2009-01-13 | Merck & Co., Inc. | Benzodiazepine CGRP receptor antagonists |
| CA2569406A1 (en) | 2004-06-04 | 2005-12-22 | Icos Corporation | Methods for treating mast cell disorders |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| WO2006001266A1 (ja) | 2004-06-23 | 2006-01-05 | Banyu Pharmaceutical Co., Ltd. | ２－アリールプリン誘導体の製造方法 |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| US7608622B2 (en) | 2004-09-24 | 2009-10-27 | Janssen Pharmaceutica Nv | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases |
| CA2577588C (en) | 2004-10-29 | 2013-09-10 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting bicyclic pyrimidine derivatives |
| WO2006050076A1 (en) | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| SE0403006D0 (sv) | 2004-12-09 | 2004-12-09 | Biovitrum Ab | New compounds |
| EP1828186A1 (en) | 2004-12-13 | 2007-09-05 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| ES2308731T3 (es) | 2005-02-16 | 2008-12-01 | Astrazeneca Ab | Compuestos quimicos. |
| WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| MX2007010404A (es) * | 2005-02-25 | 2008-01-11 | Kudos Pharm Ltd | Hidrazinometilo, hidrazonometilo y compuestos heterociclicos de 5 miembros que actuan como inhibidores de mtor y su uso como agentes anti-cancer. |
| AU2006232105A1 (en) | 2005-04-05 | 2006-10-12 | Pharmacopeia, Inc. | Purine and imidazopyridine derivatives for immunosuppression |
| EP2662082A1 (en) * | 2005-11-14 | 2013-11-13 | Ariad Pharmaceuticals, Incorporated | Administration of mTOR inhibitors |
| US20090281075A1 (en) | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| DK2069352T5 (en) | 2006-08-02 | 2017-04-03 | Cytokinetics Inc | SPECIFIC CHEMICAL UNITS, COMPOSITIONS AND PROCEDURES |
| US8268809B2 (en) | 2006-09-05 | 2012-09-18 | Emory University | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof |
| WO2008030744A2 (en) | 2006-09-05 | 2008-03-13 | Board Of Regents, The University Of Texas System | Inhibitors of c-met and uses thereof |
| US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| AR063142A1 (es) | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen. |
| ES2383370T3 (es) | 2006-10-19 | 2012-06-20 | Signal Pharmaceuticals Llc | Compuestos de heteroarilo, sus composiciones y uso de los mismos como inhibidores de proteína quinasa |
| EP2457913B1 (en) * | 2006-10-19 | 2017-04-19 | Signal Pharmaceuticals, LLC | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| EP2379561B1 (en) | 2008-11-25 | 2015-11-04 | University Of Rochester | Mlk inhibitors and methods of use |
| JP2013508456A (ja) | 2009-10-26 | 2013-03-07 | シグナル ファーマシューティカルズ， エルエルシー | ヘテロアリール化合物の合成方法および精製方法 |
| UA110697C2 (uk) | 2010-02-03 | 2016-02-10 | Сігнал Фармасьютікалз, Елелсі | ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK |
-
2012
- 2012-11-30 ES ES12798565.3T patent/ES2694413T3/es active Active
- 2012-11-30 BR BR112014013332-8A patent/BR112014013332B1/pt active IP Right Grant
- 2012-11-30 MY MYPI2014701409A patent/MY169749A/en unknown
- 2012-11-30 IN IN4037CHN2014 patent/IN2014CN04037A/en unknown
- 2012-11-30 EA EA201491083A patent/EA026390B1/ru not_active IP Right Cessation
- 2012-11-30 PE PE2014000854A patent/PE20141696A1/es not_active Application Discontinuation
- 2012-11-30 SG SG11201402766UA patent/SG11201402766UA/en unknown
- 2012-11-30 SG SG10201604558SA patent/SG10201604558SA/en unknown
- 2012-11-30 KR KR1020147017858A patent/KR102040997B1/ko active Active
- 2012-11-30 MX MX2014006590A patent/MX363034B/es unknown
- 2012-11-30 UA UAA201407398A patent/UA114496C2/uk unknown
- 2012-11-30 JP JP2014544901A patent/JP6076370B2/ja active Active
- 2012-11-30 CA CA2857155A patent/CA2857155C/en active Active
- 2012-11-30 CA CA3125862A patent/CA3125862C/en active Active
- 2012-11-30 AU AU2012304276A patent/AU2012304276B2/en active Active
- 2012-11-30 US US13/689,972 patent/US9403829B2/en active Active
- 2012-11-30 EP EP12798565.3A patent/EP2785325B1/en active Active
- 2012-11-30 CN CN201280068858.0A patent/CN104093398B/zh active Active
- 2012-11-30 WO PCT/US2012/067172 patent/WO2013082344A1/en not_active Ceased
-
2014
- 2014-05-27 IL IL232827A patent/IL232827B/en active IP Right Grant
- 2014-05-27 ZA ZA2014/03865A patent/ZA201403865B/en unknown
- 2014-05-29 NI NI201400052A patent/NI201400052A/es unknown
- 2014-05-30 PH PH12014501230A patent/PH12014501230A1/en unknown
- 2014-06-20 CO CO14134651A patent/CO6990726A2/es unknown
- 2014-07-01 EC ECIEPI20147473A patent/ECSP14007473A/es unknown
-
2015
- 2015-07-31 PH PH12015501707A patent/PH12015501707B1/en unknown
-
2016
- 2016-11-02 JP JP2016215572A patent/JP2017048227A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015500236A5 (enExample) | ||
| CN101589025B (zh) | 氨基烟酸和异烟酸的衍生物作为二氢乳酸脱氢酶(dhodh)抑制剂 | |
| JP2019517487A5 (enExample) | ||
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| MY180666A (en) | Substituted pyrazolo [3,4-b] pyridines as medicaments | |
| PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| NZ613219A (en) | Heterocyclic containing entities, compositions and methods | |
| WO2018155916A3 (ko) | 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| JP2014513110A5 (enExample) | ||
| JP2014521625A5 (enExample) | ||
| RU2016122867A (ru) | (6s,9as)-n-бензил-6-[(4-гидроксифенил)метил]-4,7-диоксо-8-({ 6-[3-(пиперазин-1-ил)азетидин-1-ил]пиридин-2-ил} метил)-2-(проп-2-ен-1-ил)-октагидро-1h-пиразино[2,1-c][1,2,4]триазин-1-карбоксамидное соединение | |
| WO2015042078A8 (en) | Substituted aminopyrimidine compounds and methods of use | |
| HK1211289A1 (en) | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| JP2011201907A5 (enExample) | ||
| ME02322B (me) | Kinazni inhibitor koji reguliše signalni put apoptoze | |
| WO2013174930A3 (en) | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| MX2014014109A (es) | Derivados de 7-oxo-4,7-dihidro-pirazolo[1,5-a]pirimidina que son utiles en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| JP2017500303A (ja) | エゼチミブ及びロスバスタチンを含む経口用複合製剤 | |
| JP5749410B2 (ja) | ジヒドロピロロ［１，２−ｃ］イミダゾリルアルドステロンシンターゼまたはアロマターゼ阻害薬の新たな形態および塩 | |
| WO2013057251A3 (en) | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| NZ730189A (en) | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one | |
| WO2016027241A1 (en) | Novel iminonitrile derivatives | |
| KR20140102200A (ko) | 약제학적 화합물 | |
| WO2016010869A3 (en) | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | |
| MX2015008288A (es) | Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. |